Advancing the health and well-being of animals and people


Principal Investigator: Kenneth Simpson

Co-Principal Investigator: David Putnam
Contact Information: Email: kws5@cornell.edu; Phone: (607) 253-3251
Sponsor: American College of Veterinary Internal Medicine Foundation
Grant Number: 10-14
Title: Development of a Novel Amikacin Delivery Method for Treatment of E. coli Associated with Granulomatous Colitis of Boxer Dogs
Annual Direct Cost: $16,550
Project Period: 08/01/10 – 07/31/11

DESCRIPTION (provided by applicant): Boxer dogs are uniquely susceptible to a severe intestinal disease known as Granulomatous colitis (GC) that causes chronic severe diarrhea, intestinal bleeding, anemia, weight loss and debilitation. Recently the disease was found to be associated with invasion of the colon wall by the bacterium E. Coli, and affected Boxer dogs have been successfully treated using antimicrobials that can attain high levels inside cells. Treatment failures occur when the E. coli is resistant to the antimicrobial used, or when the drug is not able to accumulate within cells. Boxer dogs that do not respond well to treatment are often euthanized due to a poor quality of life. In a recent study we discovered that many affected Boxer dogs (57%) have E. coli strains that are resistant to currently available antimicrobials. All of the E. coli strains isolated were sensitive to an antimicrobial called amikacin, but unfortunately this drug does not penetrate well into cells and would not be an effective treatment. We propose to modify amikacin in order to improve its ability to accumulate within macrophages and kill E. coli associated with GC. It is our hope that the study proposed herein will lead to clinical trials, and ultimately could provide a life-saving alternative to current treatment options in Boxer dogs with enrofloxacin resistant E.coli.